GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » EBITDA Margin %

Pharvaris NV (Pharvaris NV) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pharvaris NV's EBITDA for the three months ended in Mar. 2024 was $-30.70 Mil. Pharvaris NV's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Pharvaris NV's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


Pharvaris NV EBITDA Margin % Historical Data

The historical data trend for Pharvaris NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV EBITDA Margin % Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - - - - -

Pharvaris NV Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharvaris NV's EBITDA Margin %

For the Biotechnology subindustry, Pharvaris NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharvaris NV's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's EBITDA Margin % falls into.



Pharvaris NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Pharvaris NV's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-105.405/0
= %

Pharvaris NV's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-30.702/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharvaris NV  (NAS:PHVS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Pharvaris NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharvaris NV (Pharvaris NV) Business Description

Traded in Other Exchanges
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.